Particle.news

Study Finds Glioblastoma Drug Acts on DHODH Not KDM4

This finding raises the need to reassess studies that used QC6352 and could change how zavondemstat trials are designed.

Overview

  • The peer‑reviewed paper, published Tuesday in Nature Chemical Biology, shows that the experimental drug zavondemstat and the research compound QC6352 exert most of their anti‑cancer effect by blocking the enzyme DHODH rather than the histone demethylase family KDM4.
  • Researchers reached the conclusion after tests in patient‑derived glioblastoma stem cells and tumor models plus genetic and biochemical assays that linked drug sensitivity to DHODH activity and pyrimidine synthesis.
  • Because QC6352 was widely used as a tool to study KDM4 and zavondemstat entered clinical testing under the KDM4 assumption, the authors say past studies may need re‑interpretation and current trials could require changes to patient selection and endpoints.
  • To help separate the biology of each target, the team developed new compounds that selectively inhibit KDM4 without affecting DHODH so future research can test KDM4’s true role in cancer.
  • The work points to DHODH as a promising therapeutic vulnerability in glioblastoma and suggests that existing DHODH inhibitors under study for other cancers are candidates to test in brain cancer trials, while also underscoring the need for earlier, stricter target validation in drug development.